Cheson heads Lymphoma Research Foundation board

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 7
Volume 19
Issue 7

Bruce Cheson, MD, has become chair of the Lymphoma Research Foundation Scientific Advisory Board. Dr. Cheson is professor of medicine, head of hematology, and director of hematology research at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington DC. His two-year term as chair began in July 2010.

Bruce Cheson, MD, has become chair of the Lymphoma Research Foundation Scientific Advisory Board. Dr. Cheson is professor of medicine, head of hematology, and director of hematology research at the Lombardi Comprehensive Cancer Center at Georgetown University Hospital in Washington DC. His two-year term as chair began in July 2010.

Dr. Cheson's clinical interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies. He currently serves as editor-in-chief of Clinical Lymphoma, Myeloma & Leukemia and Clinical Advances in Hematology and Oncology.

The 40-member scientific board develops the foundation's research portfolio, reviews grant proposals, and makes recommendations about research priorities and funding to the New York-based foundation's board of directors.

Dr. Cheson serves on the Oncology News International editorial advisory board.

Recent Videos
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Related Content